Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 2
2011 6
2012 7
2013 1
2014 1
2015 1
2018 2
2019 7
2020 11
2021 11
2022 9
2023 11
2024 10
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions.
Meyer Sauteur PM, Beeton ML; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) study group. Meyer Sauteur PM, et al. Lancet Microbe. 2024 Feb;5(2):e100-e101. doi: 10.1016/S2666-5247(23)00344-0. Epub 2023 Nov 23. Lancet Microbe. 2024. PMID: 38008103 Free article. No abstract available.
Mycoplasma pneumoniae: gone forever?
Meyer Sauteur PM, Beeton ML; ESGMAC the ESGMAC MAPS study group. Meyer Sauteur PM, et al. Lancet Microbe. 2023 Oct;4(10):e763. doi: 10.1016/S2666-5247(23)00182-9. Epub 2023 Jun 29. Lancet Microbe. 2023. PMID: 37393927 Free article. No abstract available.
Pneumonia outbreaks due to re-emergence of Mycoplasma pneumoniae.
Meyer Sauteur PM, Beeton ML; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) study group. Meyer Sauteur PM, et al. Lancet Microbe. 2024 Jun;5(6):e514. doi: 10.1016/S2666-5247(23)00406-8. Epub 2024 Feb 8. Lancet Microbe. 2024. PMID: 38342111 Free article. No abstract available.
Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial.
Butler CC, van der Velden AW, Bongard E, Saville BR, Holmes J, Coenen S, Cook J, Francis NA, Lewis RJ, Godycki-Cwirko M, Llor C, Chlabicz S, Lionis C, Seifert B, Sundvall PD, Colliers A, Aabenhus R, Bjerrum L, Jonassen Harbin N, Lindbæk M, Glinz D, Bucher HC, Kovács B, Radzeviciene Jurgute R, Touboul Lundgren P, Little P, Murphy AW, De Sutter A, Openshaw P, de Jong MD, Connor JT, Matheeussen V, Ieven M, Goossens H, Verheij TJ. Butler CC, et al. Among authors: matheeussen v. Lancet. 2020 Jan 4;395(10217):42-52. doi: 10.1016/S0140-6736(19)32982-4. Epub 2019 Dec 12. Lancet. 2020. PMID: 31839279 Clinical Trial.
Clinical and molecular epidemiological features of critically ill patients with invasive group A Streptococcus infections: a Belgian multicenter case-series.
Peetermans M, Matheeussen V, Moerman C, De Rydt F, Thieren S, Pollet E, Casaer M, De Backer B, De Paep R, Debaveye Y, Desmet L, Desmet S, Duval EIM, Fraipont V, Geysels D, Hermans G, Lahaye F, Mathy X, Meersseman P, Meex C, Van Herck J, van Kleef-van Koeveringe S, Layios N, Wauters J, Jorens PG. Peetermans M, et al. Among authors: matheeussen v. Ann Intensive Care. 2024 Jan 29;14(1):19. doi: 10.1186/s13613-024-01249-7. Ann Intensive Care. 2024. PMID: 38286885 Free PMC article.
Emergence of the B.1.214.2 SARS-CoV-2 lineage with an Omicron-like spike insertion and a unique upper airway immune signature.
Holtz A, Van Weyenbergh J, Hong SL, Cuypers L, O'Toole Á, Dudas G, Gerdol M, Potter BI, Ntoumi F, Mapanguy CCM, Vanmechelen B, Wawina-Bokalanga T, Van Holm B, Menezes SM, Soubotko K, Van Pottelbergh G, Wollants E, Vermeersch P, Jacob AS, Maes B, Obbels D, Matheeussen V, Martens G, Gras J, Verhasselt B, Laffut W, Vael C, Goegebuer T, van der Kant R, Rousseau F, Schymkowitz J, Serrano L, Delgado J, Wenseleers T, Bours V, André E, Suchard MA, Rambaut A, Dellicour S, Maes P, Durkin K, Baele G. Holtz A, et al. Among authors: matheeussen v. BMC Infect Dis. 2024 Oct 10;24(1):1139. doi: 10.1186/s12879-024-09967-w. BMC Infect Dis. 2024. PMID: 39390446 Free PMC article.
Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024.
Antunes L, Rojas-Castro M, Lozano M, Martínez-Baz I, Leroux-Roels I, Borg ML, Oroszi B, Fitzgerald M, Dürrwald R, Jancoriene L, Machado A, Petrović G, Lazar M, Součková L, Bacci S, Howard J, Verdasca N, Basile L, Castilla J, Ternest S, Džiugytė A, Túri G, Duffy R, Hackmann C, Kuliese M, Gomez V, Makarić ZL, Marin A, Husa P, Nicolay N, Rose AMC; VEBIS SARI VE network team. Antunes L, et al. Influenza Other Respir Viruses. 2025 Mar;19(3):e70081. doi: 10.1111/irv.70081. Influenza Other Respir Viruses. 2025. PMID: 40059069 Free PMC article.
Two Years of Genomic Surveillance in Belgium during the SARS-CoV-2 Pandemic to Attain Country-Wide Coverage and Monitor the Introduction and Spread of Emerging Variants.
Cuypers L, Dellicour S, Hong SL, Potter BI, Verhasselt B, Vereecke N, Lambrechts L, Durkin K, Bours V, Klamer S, Bayon-Vicente G, Vael C, Ariën KK, De Mendonca R, Soetens O, Michel C, Bearzatto B, Naesens R, Gras J, Vankeerberghen A, Matheeussen V, Martens G, Obbels D, Lemmens A, Van den Poel B, Van Even E, De Rauw K, Waumans L, Reynders M, Degosserie J; COVID-19 Genomics Belgium Consortium; Maes P, André E, Baele G. Cuypers L, et al. Among authors: matheeussen v. Viruses. 2022 Oct 20;14(10):2301. doi: 10.3390/v14102301. Viruses. 2022. PMID: 36298856 Free PMC article. Review.
71 results